Checks egg reserve in women with multiple sclerosis
Compares ovarian reserve tests in women aged 25 to 35 with multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
Key facts
- Where
- Bordeaux, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 35 years old?
Source: NCT05754593, who can take part
Where in France
- CHU de Bordeaux - service de neurologieBordeaux, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT05754593
- Record updated
- 27 October 2026
- Original description
The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.Read full original descriptionShow less
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis, Compared to a Control Group
The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.
Inclusion: Reproductive women between 25 and 35 years old ; MS Patient : Diagnosis of multiple sclerosis based on McDonald Criteria 2017; French-speaking, without comprehension disorders ; being affiliated to health insurance ; Willing to participate and to sign informed consent.
Exclusion: History of ovarian surgery (cystectomy, annexectomy) ; Turner Syndrome ; History of chemotherapy or pelvic radiotherapy ; patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent); fragile X messenger ribonucleoprotein 1 (FMR1) premutation ; Endometriosis with a risk of ovarian reserve alteration ; Pregnant or breastfeeding women .